system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: C-Reactive Protein, Colorectal Neoplasms, Disease-Free Survival, Female, Humans, Lymphocyte Count, Lymphocytes, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Neutrophils, Retrospective Studies, Time Factors, Treatment Outcome.
user
Does postoperative lymphocyte percentage influence the long-term disease-free survival following a resection for colorectal carcinoma? Context: The aim of this study is to examine the relationship between postoperative laboratory parameters of inflammation and the disease-free survival in patients undergoing resection for colorectal cancer. Six hundred seventy-five consecutive patients who underwent an elective resection for primary colorectal cancer from October 1999 to March 2004 were included in this study. We examined the associations between cancer recurrence and white blood cell count, lymphocyte percentage, neutrophil percentage and C-reactive protein. Lymphocyte percentage on postoperative days 3 and 7 was significantly higher in patients without recurrence than in those with recurrence. Lymphocyte percentage on postoperative day 7 differed the most between the two groups. On postoperative day 7, Stage II patients with lymphocyte percentage >15% had significantly longer survival compared with the patients with lymphocyte percentage ≤ 15%. A multivariate analysis showed lymphocyte percentage ≤ 15% on postoperative day 7 to be an independent prognostic factor, along with lymph node metastases and serosal invasion. Logistic regression analysis showed that blood loss (>250 ml) and postoperative complications were significant independent predictors of lymphocyte percentage ≤ 15% on postoperative day 7.
assistant
Lymphocyte percentage ≤ 15% on postoperative day 7 is an independent prognostic factor for the patients undergoing a resection for colorectal cancer. Final Decision: yes